Underexpression of cyclin-dependent kinase (CDK) inhibitors in cervical carcinoma

被引:44
作者
Kim, YT [1 ]
Cho, NH
Park, SW
Kim, JW
机构
[1] Yonsei Univ, Coll Med, Dept Obstet & Gynecol, Seoul 120752, South Korea
[2] Yonsei Univ, Coll Med, Dept Pathol, Seoul 120752, South Korea
关键词
D O I
10.1006/gyno.1998.5134
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent studies have revealed a new family of tumor suppressor genes that directly implicate aberrant cell cycle regulation in tumorigenesis. The general function of these gene products is that they prevent cell cycle progression by directly interfering with cyclin/cyclin-dependent kinase (CDK) activation. The importance of these genes is that they are potent inhibitors of CDK. Among these cell cycle inhibitors, p(21WAF1/CIP1) and p16 have been thoroughly studied. However, the role of p(21WAF1/CIP1) and p16 in the tumorigenesis of the uterine cervix has been poorly defined. We used immunohistochemical techniques to study the expression of these cell cycle inhibitors in formalin-fixed, paraffin-embedded cervical tissue to explore the relationship between cyclin/CDK inhibitors and cervical carcinoma. Cervical tissues were analyzed from 46 patients with cervical carcinoma, 30 cases with cervical intraepithelial neoplasia (CIN) and 22 control cases who underwent hysterectomy due to benign gynecologic disease at Yonsei University College of Medicine. All CDK inhibitors were strongly expressed in the reverse cell hyperplasia and koilocytes, whereas they revealed significantly decreased expression in neoplastic tissues (P < 0.05). P16 revealed higher expressions in cases associated with human papillomavirus (NPV) (t test, P < 0.05) than in cases lacking any type of NPV. Our results were consistent with the concept that underexpression of CDK inhibitors may play an important role in neoplastic transformation in cervical carcinoma. (C) 1998 Academic Press.
引用
收藏
页码:38 / 45
页数:8
相关论文
共 40 条
  • [1] ABERRATIONS OF P16(INK4) AND RETINOBLASTOMA TUMOR-SUPPRESSOR GENES OCCUR IN DISTINCT SUB-SETS OF HUMAN CANCER CELL-LINES
    AAGAARD, L
    LUKAS, J
    BARTKOVA, J
    KJERULFF, AA
    STRAUSS, M
    BARTEK, J
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1995, 61 (01) : 115 - 120
  • [2] CYCLIN D1 IS A NUCLEAR-PROTEIN REQUIRED FOR CELL-CYCLE PROGRESSION IN G(1)
    BALDIN, V
    LUKAS, J
    MARCOTE, MJ
    PAGANO, M
    DRAETTA, G
    [J]. GENES & DEVELOPMENT, 1993, 7 (05) : 812 - 821
  • [3] RATES OF P16(MTS1) MUTATIONS IN PRIMARY TUMORS WITH 9P LOSS
    CAIRNS, P
    MAO, L
    MERLO, A
    LEE, DJ
    SCHWAB, D
    EBY, Y
    TOKINO, K
    VANDERRIET, P
    BLAUGRUND, JE
    SIDRANSKY, D
    [J]. SCIENCE, 1994, 265 (5170) : 415 - 416
  • [4] FREQUENT SOMATIC MUTATIONS AND HOMOZYGOUS DELETIONS OF THE P16 (MTS1) GENE IN PANCREATIC ADENOCARCINOMA
    CALDAS, C
    HAHN, SA
    DACOSTA, LT
    REDSTON, MS
    SCHUTTE, M
    SEYMOUR, AB
    WEINSTEIN, CL
    HRUBAN, RH
    YEO, CJ
    KERN, SE
    [J]. NATURE GENETICS, 1994, 8 (01) : 27 - 32
  • [5] Correlation between G1 cyclins and HPV in the uterine cervix
    Cho, NH
    Kim, YT
    Kim, JW
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1997, 16 (04) : 339 - 347
  • [6] WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION
    ELDEIRY, WS
    TOKINO, T
    VELCULESCU, VE
    LEVY, DB
    PARSONS, R
    TRENT, JM
    LIN, D
    MERCER, WE
    KINZLER, KW
    VOGELSTEIN, B
    [J]. CELL, 1993, 75 (04) : 817 - 825
  • [7] ELDEIRY WS, 1995, CANCER RES, V55, P2910
  • [8] GERADTS J, 1995, CANCER RES, V55, P6006
  • [9] HALL M, 1995, ONCOGENE, V11, P1581
  • [10] INHIBITION OF CYCLIN-DEPENDENT KINASES BY P21
    HARPER, JW
    ELLEDGE, SJ
    KEYOMARSI, K
    DYNLACHT, B
    TSAI, LH
    ZHANG, PM
    DOBROWOLSKI, S
    BAI, C
    CONNELLCROWLEY, L
    SWINDELL, E
    FOX, MP
    WEI, N
    [J]. MOLECULAR BIOLOGY OF THE CELL, 1995, 6 (04) : 387 - 400